**1. Introduction**

288 Atopic Dermatitis – Disease Etiology and Clinical Management

Pei, A. Y., H. H. Chan, et al. (2001). The effectiveness of wet wrap dressings using 0.1%

Rajka, G., R. Aly, et al. (1981). The effect of short-term occlusion on the cutaneous flora in

Schnopp, C., C. Holtmann, et al. (2002). Topical steroids under wet-wrap dressings in atopic

Tang, W. Y. (2000). Diluted steroid facial wet wraps for childhood atopic eczema.

Thaci, D., K. Steinmeyer, et al. (2003). Occlusive treatment of chronic hand dermatitis with

Volden, G. (1992). Successful treatment of therapy-resistant atopic dermatitis with clobetasol

Williams, H. (2006). Wet wrap bandages for 4 weeks did not differ from topical ointments

Williams, R. E. (2000). The antibacterial-corticosteroid combination. What is its role in atopic

Wolkerstorfer, A., R. L. Visser, et al. (2000). Efficacy and safety of wet-wrap dressings in

Zhai, H. and H. I. Maibach (2001). Effects of skin occlusion on percutaneous absorption: an

pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe,

propionate and a hydrocolloid occlusive dressing. *Acta Derm Venereol Suppl* 

but increased skin infections in paediatric atopic eczema. *Evid Based Med*, 11(4): 108.

children with severe atopic dermatitis: influence of corticosteroid dilution. *Br J* 

atopic dermatitis and psoriasis. *Acta Derm Venereol,* 61(2): 150-153.

dermatitis--a vehicle-controlled trial. *Dermatology,* 204(1): 56-59.

and effective. An open study. *Dermatology,* 207(1): 37-42.

dermatitis? *Am J Clin Dermatol*, 1(4): 211-215.

overview. *Skin Pharmacol Appl Skin Physiol,* 14(1): 1-10.

*Dermatology*, 200(4): 338-339.

*(Stockh),* 176: 126-128.

*Dermatol*, 143(5): 999-1004.

mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children. *Pediatr Dermatol*, 18(4): 343-348.

> The onset of asthma may be related to Th2 cytokine dominance at the time when food allergies occur several months after birth. This study investigated the effectiveness of early intervention with a Th2 cytokine inhibitor (suplatast tosilate) for prevention of asthma in infants with food allergies and atopic dermatitis. Suplatast tosilate dry syrup (6 mg/kg daily) or a histamine H1-blocker (ketotifen fumarate dry syrup: 0.06 mg/kg daily) was administered randomly to 53 infants with atopic dermatitis caused by food allergies. The primary endpoints were the incidence of asthma and the time to the onset of wheezing. The peripheral blood Th1/Th2 ratio, total IgE level, and eosinophil count were measured before and after treatment. After 24 months of treatment, the prevalence of asthma was significantly lower in the suplatast group (20.8%) than in the ketotifen group (65.6%, p < 0.01). Additionally, the time from the start of treatment to the initial episode of wheezing for infants who developed asthma was significantly longer in the suplatast group than the ketotifen group (p < 0.01). Furthermore, the eosinophil count was significantly decreased by suplatast treatment (p < 0.05), and there was a significant difference between the suplatast and ketotifen groups with respect to both the eosinophil count (p < 0.01) and the Th1/Th2 ratio (p < 0.05). The results of the present pilot study suggest that suplatast tosilate is useful for the primary prevention of wheezing and asthma in children.
